We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Malvern NanoSight NTA Applied in the Veterinary Research Institute, Brno

Product News   Jan 08, 2014

 
Malvern NanoSight NTA Applied in the Veterinary Research Institute, Brno
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

IRBM’s Advent Manufactures 13,000 Doses of COVID-19 Vaccine for Use in Phase 2/3 Clinical Trials

Product News

Advent has manufactured 13,000 doses of the novel COVID-19 vaccine candidate, ChAdOx1 nCoV-19 (now known as AZD1222) for use in the Phase 2/3 clinical trial COV002 by the University of Oxford.

READ MORE

Phase I/II Clinical Trial of COVID-19 Vaccine Begins

Product News

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology.

READ MORE

CytoSMART Technologies Announces Launch of CytoSMART Lux2 Duo Kit

Product News

The CytoSMART Lux2 Duo Kit is designed to offer a straightforward, cost-effective solution for researchers carrying out immediate side-by-side comparisons between cell cultures.

READ MORE

Like what you just read? You can find similar content on the communities below.

Applied Sciences Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE